High-throughput molecular profiles (DNA and RNA sequencing, microarray gene expression analyses, etc) are revolutionizing the way cancers are diagnosed,[@R1]--[@R4] classified,[@R5],[@R6] and treated.[@R7]--[@R9] One well-established approach to identify molecular variants (eg, genetic, epigenetic, or gene expression pattern variants) that may be causally related to complex diseases such as cancer is to identify variant patterns that are significantly enriched in groups of afflicted individuals relative to control subjects. Examples of this approach are the various genome-wide association studies designed to identify disease-causing alleles.[@R10],[@R11] While the group approach can, by design, detect genetic or gene expression patterns that are in common among groups of afflicted individuals, genetic variants/molecular patterns that are unique to specific individuals, albeit of potential clinical significance, may go undetected using the group approach. This is likely to be especially true if there are multiple possible molecular paths to the same disease state as is believed to be the case for many, if not all, cancers.[@R12]

In this study, we were interested in evaluating the impact of using a group versus a personalized approach in the analysis of gene expression profiles of a series of pancreatic cancer patients. We found that the most significant genes/molecular pathways identified among these patients, when analyzed as a group, were substantially different from the significant genes/molecular pathways identified when the analysis was performed on an individual patient basis. Our results are consistent with earlier DNA sequence studies,[@R13]--[@R15] indicating that, on the molecular level, pancreatic cancer is a highly heterogeneous disease, and as a consequence, personalized gene expression profiling is critical to the acquisition of clinically significant information.

MATERIALS AND METHODS
=====================

Tissue Collection and Cell Extraction
-------------------------------------

Patient tissues (Table [1](#T1){ref-type="table"}) were collected at St Joseph's Hospital (Atlanta, Ga) under appropriate institutional review board protocols. Following resection, the tumor tissues were grossly examined by a pathologist and then placed in cryotubes and frozen in liquid nitrogen. Samples were transported on dry ice to Georgia Institute of Technology (Atlanta, Ga), and stored at −80°C.

###### 

Patient Clinical Information at the Time of Surgery and Clinical Outcome at the Time of This Study

![](mpa-43-198-g001)

The tissue samples were examined microscopically, and the histology of ductal adenocarcinoma was verified by a pathologist. Following the examination and verification, tissue samples were embedded in cryomatrix (Shandon, Fisher Scientific, Pittsburg, Pa), and 7-µm frozen sections were cut and attached to uncharged microscope slides. Immediately after dehydration and staining (HistoGene, LCM Frozen Section Staining Kit; Life Technologies, Carlsbad, Calif), slides were processed in an Autopix (Life Technologies) instrument for laser capture microdissection (LCM). For each of the 4 patients, 3 samples from their ductal epithelial tumor cells and 3 samples of their normal ductal epithelial cells were collected. All cells were isolated by LCM to ensure purity of samples. Approximately 30,000 cells were collected for each of the 24 total samples (12 cancer and 12 normal samples).

RNA Extraction and Amplification
--------------------------------

PicoPure RNA Isolation Kit (Life Technologies) protocols were followed for RNA extraction from the LCM cells on the Macro LCM caps in 30 µL of extraction buffer. RNA quality was verified for all samples on the Bioanalyzer RNA Pico Chip (Agilent Technologies, Santa Clara, Calif). Total RNA from the above extractions was processed using Ovation Pico WTA System (NuGEN) in conjunction with the Encore BiotinIL Module (NuGEN Technologies, San Carlos, Calif), to produce an amplified, biotin-labeled cDNA suitable for hybridizing to GeneChip Human Genome U133 Plus 2.0 Arrays (Affymetrix, Santa Clara, Calif) following manufacturer's recommendations.

Microarray Data Analysis
------------------------

We generated 24 individual gene expression profiles from the 3 cancer and 3 normal biological replicate samples of the 4 patients. Affymetrix .CEL files were processed using the Affymetrix Expression Console Software version 1.1 with the Robust Multi-Array Average normalization method. The normalized expression values from all 24 samples were log~2~ transformed.

Group Analysis
--------------

The initial data contained 54,675 probe set expression values from the Affymetrix Human Genome U133 Plus 2.0 chip. For the group analysis, the log~2~-transformed values were averaged across the 12 cancer and 12 normal samples. An unpaired *t* test (*P* ≤ 0.005) was applied to identify those probe sets (350) that had significantly different expressions between all 12 cancer and all 12 normal samples. These 350 probe sets were used in the group clustering analysis. Of these 350 probe sets, the 287 unique, annotated genes were ranked by fold change (FC). The FC of each gene was calculated by subtracting the average normal value from the average cancer value. Pathway analyses were carried out using the Web-based integrated software suite MetaCore of GeneGO (<http://thomsonreuters.com/products_services/science/systems-biology/>). Applying the default cutoff *P* ≤ 0.05, the 287 genes were found to be enriched for 22 pathways.

Individual Patient Analysis
---------------------------

For the individual patient analysis, the log~2~-transformed values were averaged across each individual's cancer and normal replicate samples. From each of the patient's initial 54,675 probe sets, an unpaired *t* test (*P* ≤ 0.005) was applied to identify 188, 267, 435, and 291 probe sets that had significantly different expression between the cancer and normal replicate samples for each of the patients P1, P2, P3, and P4, respectively. As in the group analysis, these probe sets were used in individual clustering analyses (heat maps). Of these, the 148, 211, 351, and 215 unique, annotated genes for P1, P2, P3, and P4, respectively, were ranked according to FC. The FC of each gene was calculated by subtracting the average normal value from the average cancer value for each individual. These genes also were used in the pathway analyses as described above (MetaCore GeneGO software suite). Applying the default cutoff *P* ≤ 0.05, the genes were found to be significantly enriched for 15, 17, 25, and 30 pathways in P1, P2, P3, and P4, respectively. For the probe set clusterings (heat maps) in both the group and individual analyses, the log~2~-transformed values were normalized by *Z* score statistics.

Analysis of Data From the Previously Published Study of Badea et al
-------------------------------------------------------------------

Seventy-eight Affymetrix .CEL files were downloaded from the GEO Omnibus database with accession number GDS4103.[@R16] The files were processed using the Affymetrix Expression Console Software version 1.1 with the Robust Multi-Array Average normalization method, and the normalized expression values were log~2~ transformed, similarly to our sample analysis. All the 78 samples from 36 patients were used for the group analysis. For the individual analysis, the available 2 replicate cancer and 2 replicate normal samples from 3 patients were used (herein referred to as patients P5, P6, and P7; 12 samples total). Both the group and the individual analyses were performed using the methods described above. Because technical replicates (multiple assays of the same biological patient sample) rather than biological replicates (assays of multiple biological samples from the same patient), as assayed in our study, were used in the study of Badea et al,[@R16] the number of significantly differentiated genes at *P* ≤ 0.005 was more than an order of magnitude greater than that in our study. Thus, we used an unpaired *t* test with a more stringent cutoff (*P* ≤ 0.00001) than in our analysis to keep the number of significantly differentiated genes comparable to our study. Using this criterion, 17,658 significantly differentially expressed probe sets were detected, of which the 500 (330 annotated, unique genes) most significant were used for further analysis. For the individual gene analysis, the same unpaired *t* test with *P* ≤ 0.00001 identified 12, 37, and 22 significant probe sets (12, 29, and 20 annotated, unique genes) in patients P5, P6, and P7, respectively.

RESULTS
=======

Group Profiling Identifies Genes and Functional Pathways Previously Implicated in Pancreatic and Other Cancers
--------------------------------------------------------------------------------------------------------------

### Genes

In the group profiling, all 12 cancer samples were compared against all 12 normal samples, and 350 probe sets (287 genes) were found to display significant differences in expression (*P* ≤ 0.005). The clustering of these 350 probe sets presented in Figure [1](#F1){ref-type="fig"} demonstrates clear separation of the cancer and control samples. However, multiple samples taken from the same patient do not consistently cluster together, indicating heterogeneity within both the cancer and control groups.

![Hierarchical clustering of the 350 probe sets that display a significant (*P* ≤ 0.005) difference in gene expression among all cancer and normal samples. The heat map was generated by *z* score normalization of log~2~ expression values from the Affymetrix HG U133 Plus 2.0 chip. Patients are denoted as P1, P2, P3, and P4 with their associated cancer and normal biological replicate samples (ie, C1, C2, C3 and N1, N2, N3, respectively).](mpa-43-198-g002){#F1}

Table [2](#T2){ref-type="table"} presents the top 20 most significant differentially expressed genes (10 most significantly up-regulated and 10 most significantly down-regulated) between the normal and cancer samples as ranked by FC (a complete listing of significantly differentiated genes is presented in Supplemental Tables 1 <http://links.lww.com/MPA/A282> and 2 <http://links.lww.com/MPA/A283>). A summary of the previously documented significance of a representative sampling of these genes is presented in Table [3](#T3){ref-type="table"}.

###### 

The 10 Most Significantly Up-regulated and the 10 Most Significantly Down-regulated Genes in Cancer Resulting From the Group Analysis of the 287 Unique, Annotated, Significantly Differentially Expressed Genes
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###### 

Selective Genes From Table [2](#T2){ref-type="table"} Implicated in Pancreatic and Other Cancers
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### Pathways

Functional analysis was carried out with the integrated software suite MetaCore of GeneGO (<http://thomsonreuters.com/products_services/science/systems-biology/>) incorporating the 287 differentially expressed genes. The analysis identified 22 significantly enriched functional pathways (*P* ≤ 0.05, Table [4](#T4){ref-type="table"}). More than half of the 22 pathways were associated with the immune response (12/22). Oncostatin M appeared in 4 of the 12 immune response pathways. Oncostatin M is a member of a cytokine family that includes leukemia-inhibitory factor, granulocyte colony-stimulating factor, and interleukin 6, and it possesses the ability to inhibit the proliferation of cells in lines derived from several tumor types, including breast carcinoma, ovarian cancer, melanoma, glioma, and lung carcinoma.[@R17] The 2 most significantly enriched pathways involve androstenedione and testosterone biosynthesis and metabolism (ie, androgen metabolism), both of which have been found significantly altered in pancreatic cancer.[@R18] Other immune response pathways from the group functional analysis were related to interleukins IL-13, IL-17, and IL-18. Interleukin 13 was previously shown to play a pivotal role in the immunoregulatory pathway of natural killer T cells that suppress tumor immunosurveillance.[@R19] Although IL-17 seems to have been previously associated with both tumor regression and tumor growth,[@R20] the specific IL-17 immune response pathway enriched in our analysis contained the protumorigenic gene, CCL2.[@R21]

###### 

The 22 Significantly Enriched Pathways (*P* ≤ 0.05) of the Differentially Expressed Genes From the Group Analysis (287 genes)
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Personalized Profiling Identifies Additional Genes and Functional Pathways Previously Implicated in Cancer
----------------------------------------------------------------------------------------------------------

### Genes

For the personalized profiles, the gene expression data for each individual patient were analyzed identically to the group profiling analyses. The number of significantly differentially expressed probe sets between cancer and normal replicate samples of each patient (*P* ≤ 0.005) varied up to ∼2-fold between patients (P1, 188 probe sets; P2, 267 probe sets; P3, 435 probe sets; P4, 291 probe sets). The clustering of these differentially expressed probe sets for each patient is presented as heat maps in Figure [2](#F2){ref-type="fig"}.

![Supervised clustering of probe sets displaying a significant (*P* ≤ 0.005) difference in expression between normal and cancer samples for patients P1 (A), P2 (B), P3 (C), and P4 (D). The heat map was generated by *z* score normalization of log~2~ expression values from the Affymetrix HG U133 Plus 2.0 chip. Patients are denoted as P1, P2, P3, and P4 with their associated cancer and normal biological replicate samples (ie, C1, C2, C3 and N1, N2, N3, respectively).](mpa-43-198-g006){#F2}

A list of the 20 most significantly (*P* ≤ 0.005) differentially expressed genes ranked by FC (10 most significantly up-regulated and 10 most significantly down-regulated) between the normal and cancer samples for each individual patient is presented in Table [5](#T5){ref-type="table"} (a complete list of all significantly differentially expressed probe sets is presented in Supplemental Tables 1 <http://links.lww.com/MPA/A282> and 2 <http://links.lww.com/MPA/A283>). A summary of the previously documented significance of a representative sampling of these genes is presented in Table [6](#T6){ref-type="table"}.

###### 

The 10 Most Significantly Up-regulated and 10 Most Down-regulated Genes (*P* ≤ 0.005) Between Normal and Cancer Samples for Each Patient From the Personalized Profiling Analysis (Fig. [2](#F2){ref-type="fig"})
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###### 

Selective Genes From Table [5](#T5){ref-type="table"} Implicated in Pancreatic and Other Cancers
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### Pathways

As in the group analysis, functional pathway analysis was carried out on all significantly (*P* ≤ 0.005) differentially expressed, unique, annotated genes for each patient (P1, 148 genes; P2, 211 genes; P3, 351 genes; P4, 215 genes) to identify functional pathways significantly (*P* ≤ 0.05) overrepresented in the cancer samples isolated from each individual patient (Table [7](#T7){ref-type="table"}).

###### 

The Significantly (*P* ≤ 0.05) Enriched Pathways of the Annotated, Unique, Differentially Expressed Genes in P1 (148 Genes, 15 Pathways), P2 (211 Genes, 17 Pathways), P3 (351 Genes, 25 Pathways), and P4 (215 Genes, 30 Pathways)
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### Patient 1 (P1)

Five of the 15 most significantly enriched pathways in P1 are associated with the immune response. More specifically, NFAT (nuclear factor of activated T cells) is a major transcriptional regulator in T cells and recently identified as a potent immunoregulator in cancer development and as a potential target for therapeutic manipulation of the immune response in cancer patients.[@R22] Patient 1 also showed enrichment for the TCR and CD28 signaling pathways. Glutathione metabolism was also identified as a significantly enriched pathway in P1. Glutathione is known to affect the efficacy of antineoplastic interventions mainly through nucleophilic thioether formation or oxidation-reduction reactions.[@R23] The prevalence of enriched immune response and glutathione metabolism pathways may help account, thus far, for the favorable outcome in P1.

### Patient 2 (P2)

Patient 2 displayed pathways that have been implicated strongly in cancer development and invasion. Notch signaling participates in many developmental processes regulating cell differentiation, proliferation, apoptosis, adhesion, epithelial-to-mesenchymal transition, migration, and angiogenesis and can act either as an oncogene or tumor suppressor in a highly context-dependent manner.[@R24] Cell cycle disruption is a typical feature of cancer cells and results in DNA damage.[@R25] Cytoskeleton remodeling is required for cancer cell invasion and metastasis, apparent in most cancers.[@R26] Cell adhesion determines the polarity of cells and maintains the cell architecture in tissues. Cell adhesiveness is generally reduced in cancer to allow for invasiveness, extracellular matrix decomposition, and metastasis.[@R27]

### Patient 3 (P3)

Genes in P3 were enriched predominantly for cell cycle regulatory pathways (9 of a total 25 pathways). This is typical for cancer cells at an advanced stage as with P2. Like P1, P3 showed enrichment of interleukin-mediated immune responses and the glutathione metabolism pathway. Interleukin 12 is a powerful coordinator of the innate and adaptive immune responses and has been shown to have promising antitumor effects in murine tumor models.[@R28] Interleukin 12 is currently being investigated as a potential therapeutic agent against cancer.[@R29]

### Patient 4 (P4)

The most significantly enriched pathway in P4 was the WNT signaling pathway. The canonical WNT/β-catenin pathway has emerged as a critical regulator in stem cells and has also been associated with cancer in many tissues.[@R30] For P4, this particular WNT pathway involved the *frizzled family receptor 7* (*FZD7*), which was up-regulated. Up-regulation of *FZD7* has been reported in gastric and colorectal cancers.[@R31],[@R32] Patient 4 also showed enrichment of apoptotic and survival pathways. In the p53-dependent apoptosis pathway, the *BCL2L11* gene (BCL2-like 11-apoptosis facilitator), responsible for cytoplasmic transport of proapoptotic proteins BID, BMF, and BIM, is down-regulated. On the other hand, *CDK1* (cyclin-dependent kinase 1) that promotes phosphorylation of the proapoptotic *BAD* (BCL-2--associated agonist of cell death) was up-regulated in the BAD phosphorylation pathway. This is evidence for deregulation of the apoptosis and survival pathways in P4.

Significant Genes and Pathways in the Personalized Analyses Display Little to No Overlap Among Individual Patients or With Those Identified in the Group Analysis
-----------------------------------------------------------------------------------------------------------------------------------------------------------------

As shown above, both the group and the personalized analyses identified genes and pathways previously implicated in the onset/progression of pancreatic and a broad spectrum of other cancers. We were next interested in determining the degree of overlap among those genes and pathways identified as significant in each of the individual patient analyses and in the group analysis. Interestingly, we found that the degree of overlap is remarkably low. As shown in Figure [3](#F3){ref-type="fig"} (see also Supplemental Tables 1 \[<http://links.lww.com/MPA/A282>\] and 2 \[<http://links.lww.com/MPA/A283>\]), less than 6.5% (average, 3.3%) of the genes identified as significantly differentially expressed between normal and cancer cells isolated from individual patients (personalized profiles) overlap with genes identified as significantly differentially expressed across the combined patient samples (group analysis). Likewise, there is remarkably little overlap among the individual patients. For example, of the combined number of annotated genes identified as significantly differentially expressed in samples P1 and P2 (148 + 211 = 359), there was less than 1% (2 / 359 ≈ 0.006) overlap. Even between P2 and P3, samples that share the largest number of overlapping genes (8 genes), the degree of overlap is only slightly more than 1% (8 / (211 + 351) ≈ 0.014).

![Venn diagrams showing the unique, annotated genes identified as significantly differentially expressed in the group analysis and in the personalized analysis(es) of at least 1 patient.](mpa-43-198-g010){#F3}

Comparison of the most significantly overrepresented pathways identified in the personalized and group analyses resulted in similar results to the gene analyses; that is, there is relatively little overlap between pathways identified as overrepresented in the group analysis versus the personalized analyses. Furthermore, there is remarkably little overlap in overrepresented pathways among individual patients based on the personalized profiles (Fig. [4](#F4){ref-type="fig"}; Supplemental Table 3 <http://links.lww.com/MPA/A284>).

![Venn diagrams showing pathways identified as significantly enriched in the group analysis and in the personalized analysis(es) of at least 1 patient.](mpa-43-198-g011){#F4}

As shown in Figure [4](#F4){ref-type="fig"} (see also Supplemental Table 3 <http://links.lww.com/MPA/A284>), less than 5% (average, 1.7%) of the pathways identified as significantly overrepresented in individual patients (personalized profiles) overlap with pathways of genes identified as significantly differentially expressed across the combined patient samples (group analysis). In fact, pathways identified as overrepresented in 2 of the patient samples (P1 and P4) had no overlap with those identified in the group analysis. In addition, there is relatively little overlap among the individual patients. For example, of the pathways identified as significantly overrepresented in samples P1 and P2 (15 + 17 = 32), there was only 6.3% (2/32 ≈ 0.063) overlap. Even between P3 and P4, samples that share the largest number of significantly overrepresented pathways (6 pathways), the degree of overlap is less than 11% (6 / (25 + 30) ≈ 0.109).

The results of the above studies indicate that genes and pathways identified as being most significantly different between normal and cancer samples as determined by the group analysis display little or no overlap with those identified as significant by individual personalized analyses. Likewise, we found little or no overlap in genes and pathways identified as being most significantly different among individual patient samples (personalized analyses).

To determine if our findings were simply an artifact of the relatively high stringency used in identifying significantly differentiated genes (*P* ≤ 0.005), we recomputed the degree of overlap between the personalized and group analyses with a variety of cutoff values ranging from 0.05 to 0.001 Although as stringency is reduced, the total number of differentially expressed genes increases as expected, the low overlap between genes identified as significant by the group versus the personalized analyses remained remarkably low (Fig. [5](#F5){ref-type="fig"}).

![Histogram representing the percent overlap of differentially expressed genes found by group versus P1, group versus P2, group versus P3, and group versus P4 over a range of *P* values. Note that even at a nonsignificant cutoff *P* value of 0.1, the group versus personalized of P3 shows relatively little overlap (∼18%).](mpa-43-198-g012){#F5}

To address the possibility that our findings may simply be an artifact of the relatively small number of patients examined in our study, we conducted a similar analysis using data from a previously published microarray gene expression analysis of control and cancer tissue samples isolated from 36 patients.[@R16] In this earlier study, replicate assays were carried out on 3 patients, allowing us to compare the most significantly differentiated genes as determined by a group analysis (36 patient samples) versus the significantly differentiated genes determined in personalized analyses of 3 patients. Consistent with our previous findings, the results demonstrate remarkably little overlap between genes identified as significant in the group versus personalized analyses (Fig. [6](#F6){ref-type="fig"}; Supplemental Table 4 <http://links.lww.com/MPA/A285>).

![Venn diagrams showing the genes identified as significantly differentially expressed in the group analysis and in the personalized analysis(es) of at least 1 patient using data from Badea et al.[@R16]](mpa-43-198-g013){#F6}

As shown in Figure [6](#F6){ref-type="fig"} (see also Supplemental Table 4 <http://links.lww.com/MPA/A285>), less than 2% (average, 1.07%) of the genes identified as significantly differentially expressed between normal and cancer cells (*P* ≤ 0.00001) isolated from individual patients (personalized profiles) overlap with genes identified as most significantly differentially expressed (top 500 of 17,658 genes significantly differentially expressed, *P* ≤ 0.00001) across the combined patient samples. There was no overlap among patients in significantly differentiated genes.

DISCUSSION
==========

Molecular profiling is revolutionizing the way we view and treat cancer. Rather than the traditional tissue-of-origin approach to the classification and treatment of the disease, molecular profiling is providing gene-based diagnostics and therapeutics as a realistic alternative. The identification of key genes/pathways associated with various types of cancer is the foundation for both molecular diagnostics and therapeutics.

The group approach to the identification of key genes/pathways involves combining the molecular profiles of collections of samples from diseased patients to identify shared variant profiles that are distinct from those associated with nondiseased controls (eg, see Clarke et al[@R33]). Although this can be a productive approach for the detection of biomarkers and potential therapeutic targets for diseases caused by 1 or a few genes, for diseases caused by aberrations in a variety of alternative genes/pathways, the group approach may be less effective.[@R34]

Genomes can be profiled with respect to DNA sequence and with respect to gene expression (RNA quantification by microarray or RNAseq analyses, etc). The 2 approaches are complementary in that some functionally significant changes in DNA sequence may not result in changes in gene expression (eg, changes resulting in an altered protein sequence), whereas some changes in gene expression may not be associated with changes in gene sequence (epigenetic changes or changes in a gene's promoter region, etc). A number of DNA sequence analyses of tumor samples isolated from large numbers of pancreatic cancer patients indicate that, from the gene mutation perspective, pancreatic cancer is a highly heterogeneous disease,[@R13],[@R15] suggesting that pancreatic cancer cannot be characterized by a narrowly defined set of mutations across all patients.[@R35] In the present study, we were interested in further examining this question by comparing the most significantly differentially expressed genes/pathways between pancreatic cancer and control samples as determined by group versus personalized analyses of the same samples. Toward this end, we used LCM to collect 3 distinct sets (biological replicates) of normal and cancer cells from tissue samples obtained from 4 pancreatic patients. In addition, we reanalyzed data from a previous gene expression analysis of 36 pancreatic patients[@R16] and compared the most significantly differentiated genes/pathways as determined by the group analysis relative to the most significantly differentiated genes/pathways as determined by personalized analyses of 3 patients for which replicate microarray assays were performed.

Our results consistently demonstrated little to no overlap between genes/pathways identified in the group analyses relative to those identified in the personalized analyses. For example, consistent with earlier reports,[@R36] our group analysis identified MUC4 as one of the most significantly differentiated expressed genes between the normal and pancreatic cancer samples (Table [2](#T2){ref-type="table"}). Indeed, MUC4 has recently been proposed as a prime candidate for targeted drug therapy in pancreatic cancer.[@R37] In our personalized analyses, however, MUC4 was identified as significantly overexpressed in only 1 of the 7 patients examined suggesting that MUC4 therapy would likely not be effective for the majority of the patients examined in our study. Conversely, many of the genes identified as being significantly differentially expressed in individual patients (personalized profiles) were not identified as significant in the group analysis. For example, the most significantly differentially expressed gene in the cancer samples isolated from P1 is *PSCA* (prostate stem cell antigen). Interestingly, a monoclonal antibody against PSCA is currently being tested in clinical trials for both prostate and pancreatic cancer.[@R38],[@R39] Thus, whereas PSCA targeted therapy might well be expected to be effective for P1, it was not identified as being significantly overexpressed in the group analysis or in the personalized analyses of any of the other patients examined. Similarly, *ADAM* (*a d*isintegrin *a*nd *m*etalloprotease), a gene reported to be overexpressed in a number of human cancers[@R40] and identified as a potential candidate for targeted gene therapy,[@R41] was among the most significantly overexpressed genes in P4 but was not identified as being significantly overexpressed in the group analysis or in the personalized analyses of any of the other patients examined.

Collectively, our results are consistent with earlier findings indicating that, on the molecular level, pancreatic cancer is a highly heterogeneous disease.[@R13] Although targeted gene therapy is believed by many to hold great promise in the treatment of pancreatic and other cancers, a crucial step in the process is the accurate identification of appropriate candidate genes for targeted therapy. Our findings indicate that personalized and not group molecular profiling is the most appropriate approach for the identification of putative candidates for effective targeted gene therapy for pancreatic and perhaps other cancers with heterogeneous molecular etiology.
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